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Abstract
Background: Heartworm (Dirofilaria immitis) in dogs is considered endemic in Australia, but the clinical heartworm
disease caused by the heartworm is rare and prevalence is low. The mainstream prevention of the heartworm
is based on macrocyclic lactone (ML) administration. The aim of this study was to confirm endemism of the
heartworm under current Australian conditions using a cohort of recent microfilaria-positive dogs which were
on variable heartworm prevention.
Methods: A hotspot of canine heartworm antigen-positive and microfilaria-positive dogs has been detected
recently in Queensland, Australia. Blood samples from 39 dogs from Queensland and two dogs from New
South Wales were investigated for canine filarioids. Rapid antigen diagnostic tests capable of detection of D.
immitis and real-time PCR for quantification and differentiation between D. immitis from Acanthocheilonema
reconditum with quantification of microfilariae in canine blood samples, together with D. immitis specific
real-time PCR assay, were applied to microfilaria-positive dogs. The P-glycoprotein genotype was determined
to test whether Australian-sourced heartworm shared the same genetic markers as those suspected of
ML-resistance in North America.
Results: Only D. immitis was detected in the samples from Queensland and New South Wales, Australia.
Using high resolution melt real-time PCR and D. immitis specific real-time PCR, the calculated microfilaria
concentration ranged from 1 to 44,957 microfilariae/ml and from 7 to 60,526 microfilariae/ml, respectively.
DNA sequencing of the PCR products confirmed D. immitis. Fifteen of the examined dogs were on putative,
rigorous ML prevention. For the remaining dogs, compliance with heartworm prevention was unknown or
reported as inconsistent. Wild-type genotype AA-GG of the P-glycoprotein locus of D. immitis sequence has
been obtained for three blood samples. Due to the incomplete history, any suggestion of a loss of efficacy
of MLs must be treated as ‘remotely possible’. In the immediate future, records of preventative
administration and annual antigen testing would be required to determine any problems with the efficacy
of preventatives.
Conclusions: The prevalence of canine heartworm in Australia remains poorly understood. It is generally
assumed to be low by veterinary practitioners. The localised increase in the study area confirms endemism
of canine heartworm and a requirement for ongoing vigilance through annual heartworm testing to better
understand the changing distribution of canine heartworm, client compliance, as well as to detect any
change in ML-susceptibility.
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Background
Dirofilaria immitis (canine heartworm) is a parasitic
nematode responsible for the canine heartworm disease.
Transmitted from host-to-host via mosquito bites, infec-
tion largely affects the cardiopulmonary system resulting
in severe and potentially fatal disease. The disease is well-
established, mostly affecting temperate, tropical and
subtropical areas of North, Central and South America,
southern Europe, as well as Australia [1–7]. The preva-
lence of the disease is influenced by climate and topog-
raphy, but most importantly, by the presence of mosquito
vectors - ubiquitous Culex spp., Aedes spp. and Anopheles
spp. [6, 8]. Transmission occurs when mosquitoes ingest
D. immitis microfilariae (L1) as they circulate the blood of
infected animals. In the mosquito, the microfilariae moult
before migrating to the proboscis as D. immitis infective
third-stage larvae (L3) [9]. These larvae (L3) are trans-
ferred to hosts during blood meals, where migrate
throughout the blood and body towards the pulmonary
arteries and reach sexual maturity in large blood vessels
[10]. The microfilariae are first seen in 6–7 month after
the initial infection and the life span of adult female (230–
310 mm in length) and male (120–190 mm in length)
heartworms is 5–10 years [8–10].
The principal prevention for heartworm in dogs is
based on monthly oral or topical administration of
macrocyclic lactones (ML) or yearly injections of moxi-
dectin microspheres (also ML). Canine heartworm is
considered endemic in Australia, with the principal
mosquito vectors being Aedes notoscriptus and Culex
annilirostris in southeast Australia [11]. Between 1970
and 1990, there was a reported increase in heartworm
prevalence from 5 % to a peak of 30 % in New South
Wales [12–14]. Heartworm was consistently found
across all states and territories with highest rates of
prevalence found in Queensland (36 %) and Northern
Territory (90–100 %) [1, 15–18]. Current prevalence is
low even in sentinel populations such as Aboriginal
community dogs [19]. Australian dingos/wild dogs
potentially represent a reservoir in northern Queensland
based on recent small scale survey [20]. A recent 2011
heartworm antigen survey found only 2 (0.3 %)
heartworm-positive dogs out of 783 pound dogs from
New South Wales, Queensland and South Australia with
no known history of prophylaxis (Sarah Cooper, Australian
Veterinary Association Annual Conference, 20–25 May
2012, Canberra). Based on the above surveys, Australia
should be considered a region of low prevalence for heart-
worm in dogs.
Since 2005, a lack of efficacy of MLs to prevent heart-
worm infection has been reported in the USA, suggesting
the possibility that heartworm is developing resistance to
ML-preventatives [21]. Studies since have been focused on
identification of potential molecular changes that could be
associated with ML lack of efficacy [22–25]. Comparisons
of ML-resistant and susceptible D. immitis have identified
possible single nucleotide polymorphisms (SNPs) such as
the GG-GG genotype in the P-glycoprotein (P-gp) with
ivermectin-resistance [22, 23, 26]. More recently, whole
genome scans discovered over 150 markers potentially
associated with ML-resistance [27]. However, further
research is required to validate these genetic markers and
their utility for diagnostic screening [7]. At present, no
genetic test is available to differentiate ML-susceptible
from ML-resistant field specimens. Compared to USA,
lack of efficacy of MLs to prevent canine heartworm has
not been reported in Australia.
The aim of this study was to confirm endemicity of the
canine heartworm under current Australian conditions
using a cohort of recent heartworm-positive dog material
which were on variable heartworm prevention. Rapid
diagnostic tests capable of detection, differentiation and
quantification of microfilaria and species specific real-time
PCR assays were applied to blood or microfilaria from
positive dogs. The P-gp genotype was determined to
ascertain whether these Australian heartworms shared the




Samples tested included two cohorts. The first cohort,
samples (FVS-CN, n = 39) were from those that tested
positive using in clinic antigen tests. The second cohort,
samples (FVS-HW, n = 2) were from recent clinical cases
currently treated for canine heartworm at the Faculty of
Veterinary Science, University of Sydney.
Blood samples FVS-CN#1 to FVS-CN#39 were col-
lected in April to June, 2015, from dogs in Queensland,
Australia (Table 1). Dogs were located in the Mackay
region (FVS-CN#1, FVS-CN#3 to FVS-CN#34, FVS-
CN#36 to FVS-CN#39), Cairns (FVS-CN#2) and Too-
woomba (FVS-CN#35) (Additional file 1: Table S1). All
samples initially tested positive using an in-clinic Witness
Dirofilaria® (Zoetis, Australia), a Rapid Immuno-Migration
(RIM®) Assay for detection of adult female D. immitis
(heartworm) antigen in dogs positive by veterinary practi-
tioners. To confirm the result, we performed DiroCHEK®
(Zoetis, Australia via Vetpath Laboratory Services, Western
Australia) an enzyme-linked immunosorbent assay (ELISA)
for the detection of adult D. immitis antigen and Knott’s
test (Vetpath Laboratory Services, Western Australia). For
each dog only locality, the age, presence of suspected heart-
worm associated clinical signs and history of heartworm
prevention were available. Heartworm prevention compli-
ance was reported as ‘rigorous’ if the client indicated year
round administration with appropriate product (no actual
evidence of purchase and administration was provided),
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Table 1 Summary of diagnostics for heartworm (Dirofilaria immitis) in dogs from Australia
Animal (dogs) Immunology Parasitology Molecular diagnostics (real-time PCR) Heartworm prevention
FVS-CN# Age (yrs) Witnessa DiroCHEKb Knott’s test Dog (Ct)
c Filaria (Mff#/ml)d D. immitis (Mff#/ml)e Clinical signs Compliancef Active
1 6.0 Positive Positive Positive – – 7 – Inconsistent na
2 9.0 Positive Positive Positive – – – Present Yes Selamectin
3 2.0 Positive Positive Positive 27.6 10 14 – na na
4 7.5 Positive Positive Positive 35.0 165 147 Present na na
5 3.0 Positive Positive Positive 31.1 10 9 – na na
6 6.7 Positive Positive Positive 26.8 – – – Yes Milbemycin oxime
7 8.0 Positive Positive Positive 26.4 835 571 – Yes Ivermectin
8 10.0 Positive Positive Positive 24.9 215 204 – na na
9 3.8 Positive Positive Positive 26.2 118 52 – Yes Milbemycin oxime
10 5.1 Positive Positive Positive 27.7 46 15 – inconsistent na
11 na Positive Positive Positive 24.5 23,376 60,527 – inconsistent na
12 2.8 Positive Positive Positive 30.2 24 460 – Yes Moxidectin
13 2.0 Positive Negative Positive 24.3 126 77 Present inconsistent na
14 4.0 Positive Positive Positive 32.9 3 0 – na na
15 7.0 Positive Positive Positive 22.4 912 610 – na na
16 2.0 Positive Positive Positive 23.0 940 261 – na na
17 3.0 Positive Positive Positive 24.9 165 518 – na na
18 2.0 Positive Negative Positive 25.2 124 239 – na na
19 2.0 Positive Positive Positive 24.6 34 261 Present Yes Milbemycin oxime
20 3.0 Positive Positive Positive 26.3 1,184 3,471 – na na
21 2.0 Positive Positive Positive 28.6 36 130 – Yes Milbemycin oxime
22 13.0 Positive Positive Positive 28.2 70 52 Present Yes Milbemycin oxime
23 2.0 Positive Positive Positive 28.8 60 416 – Yes Milbemycin oxime
24 3.0 Positive Positive Positive 38.8 1 77 – na na
25 5.0 Positive Positive Positive 26.6 4,543 8,042 Present inconsistent na
26 3.0 Positive Positive Positive 24.5 58 319 – inconsistent na
27 3.0 Positive Positive Positive 34.1 16 157 – inconsistent na
28 10.0 Positive Positive Positive 28.8 11,214 1,478 – inconsistent na
29 2.0 Positive Positive Positive 36.7 – 12 – na na
30 10.0 Positive Positive Positive 24.3 2,022 9,551 – Yes Ivermectin
31 7.0 Positive Positive Positive 23.9 177 217 – na na












Table 1 Summary of diagnostics for heartworm (Dirofilaria immitis) in dogs from Australia (Continued)
33 na Positive Positive Positive 28.8 41 45 Present inconsistent Ivermectin
34 5.5 Positive Positive Positive 23.7 8,745 15,976 Present Yes Milbemycin oxime
35 6.0 Positive Positive Positive 37.4 198 320 – n/a na
36 4.0 Positive Positive Positive 24.8 44,966 1,866 – n/a na
37 2.1 Positive Positive Positive 35.6 31 5,717 – Yes Milbemycin oxime
38 7.0 Positive Positive Positive 28.8 142 4,505 – Yes Moxidectin
39 1.8 Positive Positive Positive 27.4 773 276 – Yes Milbemycin oxime
aIn-clinic Witness Dirofilaria® (Zoetis, Australia), a Rapid Immuno-Migration (RIM®) Assay for detection of adult female D. immitis (heartworm) antigen in dogs
bDiroCHEK® (Zoetis, Australia) an enzyme-linked immunosorbent assay (ELISA) for the detection of adult D. immitis antigen
cCanine ß-actin real-time PCR assay for sample adequacy evaluation, Ct <30 is considered adequate (n = 28, 72 %)
dArthropod-borne filarioids high-resolution melt (HRM) real-time PCR assay targeting filarioid mitochondral 12S rRNA gene, reported as microfilaria (Mff) in ml of blood
eD. immitis species-specific real-time PCR targeting cox1 gene fragment, reported as microfilaria (Mff) in ml of blood
fRigorous compliance (Yes) was noted if client indicated year round administration with appropriate product, ‘inconsistent’ compliance if heartworm preventions were missed or intermittently administrated or incorrect












‘inconsistent’ if heartworm preventions were missed or
intermittently administrated or incorrect dose adminis-
tered, and ‘unknown’ if such information was not available
or was unknown. Anonymous refrigerated blood samples
FVS-CN#1 to FVS-CN#39 were processed at the Faculty of
Veterinary Sciences, University of Sydney for this study
(Additional file 1: Table S1).
Two recent (February, 2016) microfilaria-positive dog
blood samples were provided by the University Veterinary
Teaching Hospital, Sydney (UVTHS), Faculty of Veterinary
Science, University of Sydney. Both dogs were previously
domiciled in Queensland, Australia. For both FVS-HW#1
(1,300 microfilariae/ml) and FVS-HW#2 (14 microfilariae/
ml) the microfilaria concentration was evaluated using
microcapillary test. Briefly, the buffy coat was observed for
the presence of microfilaria under the microscope in micro-
hematocrit tubes after centrifugation of EDTA blood. FVS-
HW#1 positivity was also assessed with modified Knott’s
test. Dog FVS-HW#1 was referred to UVTHS for heart-
worm disease prior to treatment, blood was collected and
tested positive using Anigen Rapid Canine Heartworm
(CHW) Ag 2.0 Test Kit (Bionote; Life Bioscience, Oakleigh,
Australia) a chromatographic immunoassay for the qualita-
tive detection of canine D. immitis antigen; the dog stayed
in Mackay, Queensland prior to arriving in Sydney, New
South Wales. Dog FVS-HW#2 was undergoing heartworm
treatment with melarsomine (Immiticide®, Merial), and
blood was collected prior to second treatment, at the time
blood of FVS-HW#2 was negative using Anigen Rapid
Canine Heartworm (CHW) Ag 2.0 Test Kit; the dog was
from Brisbane, Queensland but it was rehomed from else-
where (unknown source) in Queensland. For both FVS-
HW#1 and FVS-HW#2, heartworm prevention was inter-
mittent. In addition, canine DNA isolated from a dog domi-
ciled in Nadi, Fiji (FIJI-HW#1) from 2009 was included in
the study as initial positive control.
Isolation and confirmation of canine blood DNA
Blood samples (EDTA, 70–200 μl) from FVS-CN#1 to
FVS-CN#39 were kept frozen for 8–10 months at -20 °C
and refrigerated blood (200 μl) from FVS-HW#1 and FVS-
HW#2 was used for DNA isolation. The genomic DNA
from samples FVS-CN#7 to FVS-CN#39, FVS-HW#1 and
FVS-HW#2 was isolated using a combination of MoBio
PowerMag® Blood Isolation Kit (lysis) and PowerMag®
Microbiome RNA/DNA Isolation Kit (magnetic separation)
(Mo-Bio Laboratories; GeneWorks, Thebarton, Australia)
optimised for KingFisher® Duo (Thermo-Fisher Scientific,
Scoresby, Australia). Isolation was processed in batches of
11 blood samples and an extraction blank. Initial lysis was
according to the Blood kit isolation part with modification
to the step of white blood cell (WBC) lysis (650 μl of the
red blood cell lysate and 450 μl of PowerMag® WBC lysis
solution). DNA isolation was processed with 700 μl of the
WBC supernatant in the KingFisher® Microtiter Deep Well
96 plate as suggested by the Microbiome kit protocol.
Samples were eluted in 70 μl of ClearMag® RNase-Free
water. Genomic DNA from samples FVS-CN#1 to FVS-
CN#6 was isolated using Isolate II Blood DNA Kit (BioLine,
Australia) and eluted in 100 μl Tris buffer (pH = 8) as per
the manufacturer’s protocol. DNA concentrations were
determined by the NanoDrop 1000 Spectrophotometer
(Thermo-Fisher Scientific, Scoresby, Australia). DNA was
stored in aliquots at -20 °C until further use.
Buffy coat with 1–2 microfilaria from FVS-HW#2 was
collected using a tuberculin syringe and needle from the
micro-haematocrit tube after centrifugation. DNA was
isolated using the MoBio Kits on KingFisher as
described above.
To verify presence of dog DNA, we utilised a real-time
PCR to amplify partial (276 bp) canine ß-actin, primers
(S0588) Actin F2: 5′-ACC ACT GGT ATT GTC ATG
GAC TCT G-3′ and (S0589) Actin R2: 5′-GCT CTT
CTC CAG GGA GGA CGA-3′ [28]. The PCR cycling
conditions included initial step at 95 °C for 3 min
followed by 40 two-step cycles at 95 °C for 5 s and 60 °C
for 15 s. The real-time PCR reaction mixture (20 μl)
included 10 μl of SensiFAST SYBR No-ROX Kit (Bioline,
Eveleigh, Australia), each primer at 400 nM concentra-
tions, PCR-grade water, and 2 μl of DNA template. The
real-time PCR was carried out on a CFX96 Touch™
Real-Time PCR Detection System with the correspond-
ing CFX Manager v.3.1 software (BioRad, Gladesville,
Australia). The arbitrary real-time PCR threshold was
determined automatically using default settings and Ct-
values reported.
Arthropod-borne filarioids real-time PCR
A high-resolution melt (HRM), real-time PCR assay was
performed using primers designed by Wongkamchai et
al. [29] for the detection of Dirofilaria immitis, Brugia
malayi and B. pahangi in blood samples. Primers
(S0579) (F: 5′-TTT AAA CCG AAA AAA TAT TGA
CTG AC-3′) and (S0580) (R: 5′-AAA AAC TAA ACA
ATC ATA CAT GTG CC-3′) target approximately 110–
120 bp long partial sequence of the filarioid mitochon-
drial 12S rRNA gene. The assay is capable of amplifying
potentially all filarial nematode species [29, 30]. The
real-time PCR reaction mixture (20 μl) included 10 μl of
SensiFAST HRM mix (Bioline), each primer at 400 nM
concentrations, 4.4 μl of PCR-grade water, and 4 μl of
DNA template. Positive control plasmids with DNA for
D. immitis and Acanthocheilonema reconditum 12S
rRNA gene were synthetised by GeneArt (Thermo-
Fisher Scientific, Scoresby, Australia).
To optimize conditions with SensiFAST HRM mix
(BioLine, Australia), real-time PCR efficiency was evalu-
ated across thermal gradient from 59 °C to 62 °C against
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ten-fold serial dilutions (ranging from 1.96 × 105 to
1.96 × 100 copies per reaction) of a known concentration
of plasmid DNA containing the D. immitis 12S rRNA
gene analysed in triplicate. The reaction conditions were
set with an initial polymerase activation step at 95 °C for
3 min followed by 40 two-step cycles at 95 °C for 5 s
and 59 °C to 62 °C for 15 s. The HRM cycle was set
between 60 °C and 90 °C, with increments at 0.2 °C
intervals. The real-time PCR was carried out on a
CFX96 Touch™ Real-Time PCR Detection System with
the corresponding CFX Manager v. 3.1 software
(BioRad, Australia). For each sample CFX Manager v.
3.1 reported Ct-values and copy numbers based on
standard curve of the positive control. The arbitrary
real-time PCR threshold was set to a single threshold at
100 rfu. To plot a normalised curve of decreasing fluor-
escence with increasing temperature the Precision Melt
Software v. 1.2 (Bio-Rad, Australia) was used. Each run
included at least one negative (NTC, non-target control)
control.
The optimised filarial 12S rRNA gene real time PCR
was run as above with annealing temperature set to 62 °
C with reaction efficiency (90–110 %) and the limit of
detection determined to be greater or equals to 196 gene
copies of 12S rRNA gene per reaction. The optimised
real-time PCR was used to quantify microfilaria concen-
trations in blood samples and sample FVS-HW#2 (1,300
microfilariae/ml) used to calibrate conversion to micro-
filaria for each sample (Additional file 1: Table S1). Each
real-time PCR run included duplicate serial dilutions of
plasmid DNA (D. immitis, A. reconditum plasmids). All
DNA samples were run once. If no or > 35 Ct-values
(negative samples and late amplifiers, respectively) were
returned, the reactions were re-run. All samples with <
35 Ct-values were sent for DNA purification and subse-
quent DNA sequencing with amplification primers at
Macrogen Inc. (Seoul, Korea). To generate normalised
melting curves and difference melting curves, pre- (70–
71 °C) and post- (76–77 °C) melt normalisation regions
were set to define the main temperature boundaries of
the normalised and difference plots. The Precision Melt
Software v. 1.2 then assigned each sample to a cluster
using default settings.
Dirofilaria immitis specific real-time PCR
A real-time PCR assay was performed for detection of
D. immitis using primers designed by Rishniw et al. [28]
and applied by Rojas et al. [30]. Primers (S0582) (F: 5′-
AGT GTA GAG GGT CAG CCT GAG TTA-3′) and
(S0583) (R: 5′-ACA GGC ACT GAC AAT ACC AAT-
3′) specifically target a cox1 gene fragment (~203 bp) for
D. immitis. The real-time PCR reaction mixture (20 μl)
included 10 μl of SensiFAST SYBR No-ROX Kit (Bioline,
Australia), each primer at 400 nM concentrations, 4.4 μl
of PCR-grade water, and 4 μl of DNA template. First, a
thermal gradient PCR assay from 59 °C to 62 °C was
performed to determine optimum annealing tempera-
tures for the pair of primers using SensiFAST SYBR No-
ROX kit (Bioline, Australia). The reaction was run with
triplicate ten-fold serial dilutions (1.96 × 102 to 1.96 ×
107 copies per reaction) of a known concentration of
plasmid DNA containing the D. immitis cox1 gene
synthetised by GeneArt (Thermo Fisher, Australia) and
with negative (no template) controls. Amplification was
performed as follows: initial denaturing step at 95 °C for
3 min, followed by 40 cycles of denaturing (5 s at 95 °C),
annealing (15 s from 59 °C to 62 °C). A final melting
curve was produced by heating the product from 60 °C
to 90 °C for 5 s at 0.5 °C increments. The real-time PCR
assay was performed on a CFX95 Touch™ Real-Time
PCR Detection System (BioRad Laboratories, Inc.,
Australia). Threshold cycle (Ct) values and standard
curve were determined CFX Manager ™ Software v. 3.1
(Bio-Rad). An annealing temperature of 62 °C was found
optimal and used in subsequent amplification reactions.
The final optimised real-time PCR run consisted of
samples FVS-CN#1 to FVS-CN#39, a no-template con-
trol and a non-target control with additional duplicate
ten-fold serial dilutions of the plasmid DNA (1.96 × 107
to 1.96 × 102 copies per reaction) to assess sensitivity.
The optimised real time PCR included annealing
temperature set to 62 °C with reaction efficiency (90–
110 %) and the limit of detection determined to be ≥ 196
cox1 gene copies per reaction. Using CFX Manager ™
Software Version 3.1 (Bio-Rad), Ct-values were deter-
mined and a standard curve produced to evaluate assay
efficiency. Samples which amplified with Ct-values were
sent for DNA purification and sequencing at Macrogen
Inc. (Seoul, Korea).
Characterisation of Dirofilaria immitis P-glycoprotein locus
sequence
To obtain PCR amplicons of P-glycoprotein locus of D.
immitis (P-gp) we initially used DNA directly isolated
from blood PCR. To improve success of the P-gp ampli-
fication, we then used a whole genome amplification
step of the DNA isolated from blood. Whole genome
amplification (WGA) was carried out using the illustra
GenomiPhi V2 DNA Amplification Kit (GE Healthcare,
Parramatta, Australia) using 1 μl of gDNA extracted
from the canine blood. For WGA, we primarily focused
on DNA samples with reported rigorous compliance
with heartworm preventatives (Table 1). Amplification of
the P-pg fragment was accomplished with primer pair,
Pgp1sens (S0592) (5′-GGA CAA TTA TCC GGT GGT
CA-3′) and Pgp1antisens (S0593) (5′-TCG CAA ATT
TCC TCC CAC TT-3′) [22, 23]. All PCR amplifications
were carried out using MyTaq™ Red Mix (BioLine,
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Australia). Primers were added at a final concentration
of 0.25 μM each. A final reaction volume of 25 μl for the
first PCR was run using the following cycling conditions:
95 °C for 15 s, 56 °C for 5 s, and 72 °C for 15 s for 35 -
cycles with 2 μl of the isolated DNA or 2 μl of 1:50 dilu-
tion of the GenomiPhi amplified DNA. All reactions
were initiated at 95 °C for 5 min and concluded with
72 °C for 5 min. The PCRs were run in a Veriti PCR
cycler (Life Sciences, Australia) alongside sterile PCR-
grade water as negative control. Resulting products were
resolved in 1.5 % (w/v) agarose gel. The PCRs were run
in a Veriti PCR cycler (Life Sciences, Australia) alongside
sterile PCR-grade water as negative control. Resulting
products were resolved in 1.5 % (w/v) agarose gel. PCR
products were directly sequenced using amplification
primers at Macrogen Ltd. (Seoul, Korea). Sequences
were assembled, aligned with a reference wild type P-gp
locus sequence (HM596853) and/or BLAST analysed
using CLC Main Workbench 6.9.1 (CLC bio, Denmark).
Results
Patent microfilaraemic dogs in coastal Queensland,
Australia
All 39 dogs (FVS-CN#1 to FVS-CN#39) were initially
positive using an in-clinic Witness Dirofilaria® (Zoetis,
Australia) test for presence of female D. immitis antigen.
A reference ELISA DiroCHEK® (Zoetis, Australia)
confirmed presence of female D. immitis antigen in 95 %
(37/39, 2 false negative samples: FVS-CN#13 and FVS-
CN#18) of dogs and microfilaria were demonstrated in
all 39 samples using a modified Knott’s test (Table 1,
Fig. 1).
In the dataset presented with microfilaria (FVS-CN#1
to FVS-CN#39), 41 % of dogs were apparently compliant
with monthly heartworm prevention (n = 15) (Fig. 1a).
For the remaining dogs compliance with heartworm pre-
vention was unknown or reported as inconsistent
(Table 1). Most heartworm prevention was based on
milbemycin oxime (67 %, n = 10) followed by ivermectin
(n = 2), moxidectin (n = 2) and selamectin (n = 1). The
average age of the dogs was 5 years 6 month (min. 1 year
9 month; max. 13 years); seventeen dogs (43 %) were
three years or less (five on monthly milbemycin oxime,
one on monthly moxidectin) (Fig. 1b). Eight dogs were
in the category of over six years and up to nine years
(two on monthly milbemycin oxime, and single dogs on
moxidectin, selamectin and ivermectin) (Additional file
1: Table S1).
DNA from FVS-CN#1 to FVS-CN#39 was successfully
purified and canine ß-actin amplified (Ct values: 22.44 to
28.84) from 72 % (28/39) canine blood samples. Nine
(23 %, 9/39) DNA from blood samples amplified DNA
with higher Ct-value (< 30), and two (5 %, 2/29) DNA
samples (FVS-CN#1 and FVS-CN#2) did not amplify
canine ß-actin control gene (Table 1). FVS-HW#1, FVS-
HW#2 and FIJI-HW#2 returned adequate Ct-values 25.88,
29.76 and 25.31 in canine ß-actin assay, respectively. All
blank DNA samples remained negative in the canine ß-
actin assay.
Presence of Dirofilaria immitis using arthropod-borne
filarioids real-time PCR with HRM and DNA sequencing
In total, 36 FVS-CN samples (36/39) returned < 40 Ct-value
(Additional file 1: Table S1). The calculated microfilarial
concentration ranged from 1 (FVS-CN#24) to 44,957
(FVS-CN#36) microfilariae/ml (Table 1). Three distinct
clusters were produced with the HRM analysis of 12S





































heartworm prevention & dogs age
a b
Fig. 1 Canine heartworm Dirofilaria immitis in Australian dogs. Heartworm prevention compliance for 39 dogs was reported as ‘rigorous’
compliance if client indicated year round administration with appropriate product (no actual evidence of purchase and administration
was provided), ‘inconsistent’ compliance if heartworm preventions were missed or intermittently administrated or incorrect monthly dose
administered, and ‘unknown’ if such information was not available or was unknown. The active in prevention of dog heartworm is colour
indicated (a). The age of dogs is colour indicated (b)
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returned Ct-values and positive control Dirofilaria immitis
and Acanthocheilonema reconditum (Fig. 2, Additional file
1: Table S1). A single sample FVS-CN#24 was excluded
from HRM analysis, because of calculated low copy num-
ber (5) and non-reliable melt profile. Cluster 1 included D.
immitis positive control (high copy numbers) and the ma-
jority of dog blood samples (n = 30; 3–44,957 microfilariae/
ml). Cluster 2 included D. immitis positive control (low
copy numbers) and 4 dog blood samples (FVS-CN#10, #27,
#31, #32; 15–177 microfilariae/ml). The remaining dog
sample FVS-CN#3 clustered within Cluster 3 of A. recondi-
tum controls, but with a variable HRM profile due to late
amplification (Ct-value = 36.29) (Fig. 2; Additional file 1:
Table S1). To confirm the species identification, 33 PCR
products were submitted for DNA sequencing. Only 17/33
(51 %) samples yielded DNA sequencing data denoting D.
immitis and A. reconditum. All DNA sequence data were
identical to D. immitis 12S rRNA gene reference sequence
(FN391554), including the suspected sample FVS-CN#3
that clustered within Cluster 3 of A. reconditum controls
(Table 1, Additional file 1: Table S1).
Presence of Dirofilaria immitis using diagnostic real-time
PCR and DNA sequencing
In total 36 FVS-CN samples (36/39) were considered D.
immitis-positive returning < 37 Ct-value (Additional file
1: Table S1). The calculated microfilarial concentration
ranged from 7 (FVS-CN#1) to 60,526 (FVS-CN#11)
microfilariae/ml (Table 1). One sample (FVS-CN#14)
was considered suspect for D. immitis with Ct-value of
39.93 (0.035 microfilariae/ml); a repeated run yielded no
Ct-value. All positive (n = 36) samples yielded DNA
sequences matching D. immitis cox1 gene (Table 1, Add-
itional file 1: Table S1). All but sample FVS-CN#29 had
DNA sequences 100 % identical with D. immitis cox1
gene reference sequence (NC_005305). FVS-CN#29
included unambiguous AAT > AGT (Asn > Ser) single
nucleotide non-synonymous polymorphism at position
539 according to the reference gene.
FVS-HW#1, FVS-HW#1 and FVS-FIJI#1 returned
positive result of D. immitis (Ct-values: 25.76, 29.82 and
35.47, respectively), DNA sequences were 100 % identi-
cal with D. immitis cox1 gene reference sequence
(NC_005305).
Wildtype form of Dirofilaria immitis P-glycoprotein locus
in Australia
Wild-type genotype AA-GG of the P-glycoprotein locus
of D. immitis (P-gp) sequence has been obtained for
three blood samples (rigorous prevention group: FVS-
CN#11, FVS-CN#34 and inconsistent prevention group:
FVS-CN#37). Other samples did not yield sufficient P-
gp PCR product for DNA sequencing. Whole genome
amplification prior PCR amplification using P-gp
primers yielded DNA sequence with top BLAST hits
from the dog genome.
Discussion
It is important for the control of canine heartworm that
preventatives remain efficacious, and compliance with
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Fig. 2 HRM real-time qPCR analysis for the identification of arthropod-borne filarioids in Australia dogs. Normalized melting curves (a) and difference
melting curves (b). Curves include positive controls of Acanthocheilonema reconditum (green) and Dirofilaria immitis (red, blue). To generate normalised
melting curves and difference melting curves, pre- (70–71 °C) and post-melt (76–77 °C) normalisation regions were set to define the main temperature
boundaries of the normalised and difference plots. The Precision Melt Software v. 1.2 (BioRad) then assigned each sample to a cluster (Clusters 1–3)
using default settings. Single dog sample was assigned to A. reconditum (light green; note the ambiguous melting profile in differential melting graph
b), however DNA sequencing matched D. immitis 12S rRNA gene reference sequence (FN391554)
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treatments and heartworm antigen testing is practised. In
this study, a large proportion of the dogs with microfilariae-
mia were reportedly on rigorous monthly heartworm
prevention with either milbemycin oxime, ivermectin or
selamectin. All monthly heartworm preventatives undergo
rigorous experimental testing prior to their registration
[31]. It is expected that such preventatives are demon-
strated to have 100 % efficacy [31].
Two important caveats need to be taken into account
when considering rational prevention and compliance:
(i) residual activity and (ii) age of D. immitis present in
the dog. For (i), the residual activity of milbemycin
oxime, ivermectin or selamectin lasts only several days,
therefore it is expected that monthly doses remove all
larval stages that accumulated over the past 30 days,
implying that all D. immitis need to be less than 30 days
old. Subsequently, the efficacy for D. immitis, of the vari-
ous MLs depends on the age of the parasite (ii). The
efficacy is 100 % for 30 day-old D. immitis based on
registration for products with milbemycin oxime,
ivermectin or selamectin. A single dose of ivermectin or
selamectin applied 60 days after the infestation remains
100 % efficacious but decreases to 95 % for milbemycin
oxime (see Table 1 in [32, 33]). In other words, compli-
ance with monthly administration has to be strict with
milbemycin oxime, because comparative studies have
shown that milbemycin oxime is not as effective for ≥
30 day-old D. immitis in dogs when compared with iver-
mectin [8, 33, 34]. Therefore, if a monthly treatment
with milbemycin is missed, a small proportion of D.
immitis may be able to develop to adults and produce
microfilaria.
An incomplete compliance is a real possibility in our
cohort, because a large portion of D. immitis-positive
dogs was on milbemycin oxime. Inadvertently missing
three consecutive monthly doses means potentially four
month-old D. immitis exist before the next 12 doses are
applied; in such circumstances, McCall et al. [34]
demonstrated only 41 % efficacy of milbemycin oxime
against D. immitis. Alternatively, it can be a reflection of
larger market share of products with milbemycin oxime
for heartworm prevention over other MLs in the locality.
To document any loss of efficacy to MLs, a full history
of prevention and annual antigen test would be required
[35]. Therefore, a reduced efficacy of MLs in these
Australian cases must be treated as ‘remotely possible’
due to incomplete information [21].
The putative ‘rigorous’ canine heartworm prevention
should have halted development of D. immitis adults
and abrogated any microfilariaemia. Loss of efficacy for
milbemycin oxime, ivermectin or selamectin would be a
major concern for veterinarians, pet owners and
suppliers in Australia. The current study documents the
presence of a focus of heartworm prevalence, but much
more complete histories and testing regimes are needed
to indicate whether resistance is present or developing
in the region. In future suspected cases in Australia, a
‘microfilaria suppression test’ should be considered [23].
For example a microfilaricide, either ivermectin (50–
200 mg/kg) or milbemycin oxime (500–1,000 mg/kg),
should be applied to dogs to eliminate microfilaria. In
such a microfilaria suppression test, loss of efficacy
would be demonstrated, if > 75 % of microfilariae remain
one week after administration of the microfilaricide [23].
Currently, it is not known whether microfilaria suppres-
sion tests have been considered for these microfilaria-
positive dogs.
Only the wild-type P-gp genotype of D. immitis was
detected in Australian samples. In this study we did not
document the GG-GG P-gp genotype of D. immitis associ-
ated with ivermectin-resistance [7, 22, 23]. Despite the
published association, any direct causal effect of the GG-
GG genotype has not been demonstrated [7, 22, 23]. Our
P-gp amplification varied from the original approach [22,
23]. Firstly, only stored frozen blood was available and
therefore we could not assess individual microfilaria.
Secondly, published P-gp amplification used full genome
amplification using Repli-g® (Qiagen), while we employed
GenomiPhi V2 DNA Amplification Kit (GE Healthcare).
Both kits use multiple displacement amplification, but have
been shown to give different yields of DNA and variable
genome amplification coverage [36]. It is plausible that the
use of GenomiPhi to amplify DNA caused miss-priming of
the P-gp oligonucleotides and subsequent PCR amplifica-
tion of non-specific products. Further investigations into
the genetic identity of Australian D. immitis isolates are
potentially valuable for comparative purposes with those
from North America and Europe.
Conclusion
For patent microfilariaemic dogs, administration of
heartworm preventatives without treatment with mel-
arsomine dihydrochloride to eliminate adult worms
has the potential to select a population of D. immitis
resistant to heartworm preventatives [31]. In Australia,
heartworm prevention is ubiquitous and annual
testing or testing prior yearly ML administration is
only rarely undertaken, because heartworm disease is
now rare. Therefore, this situation may allow for the
detection of asymptomatic microfilariaemic dogs that
are on monthly prevention. Most of the monthly doses
will rapidly remove microfilaria, however the non-
lethal effect on the adult D. immitis female may result
in the reappearance of microfilariae before the next
monthly dose is administered and especially if further
doses are missed. These microfilariaemic dogs represent
local reservoirs, increasing the likelihood of transmission to
dogs that missed more than one monthly heartworm
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prevention. This scenario is plausible for the present cohort
of dogs which were domiciled within a small area in coastal
Queensland, Australia. Currently, no information is avail-
able about the extent of this phenomenon in Australia.
These findings demonstrate that heartworm is en-
demic in Australia. Strict prevention according to the
label of the preventative and annual heartworm test
should be practiced across Australia, despite most
areas are currently considered of low prevalence. The
low endemic status of heartworm status in Australia is
currently a limiting factor for the development of a
transmission model for heartworm.
Additional file
Additional file 1: Table S1. Summary of the Dirofilaria immitis
diagnostics. (XLSX 16 kb)
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